NCT06757894

Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma

Efficacy and Safety of Zuberitamab and Bendamustine Combination Treatment Followed by Monotherapy Maintenance in Treatment-naïve Follicular Lymphoma: an Open-label, Prospective, Multicenter, Single-arm Phase II Clinical Study

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, single-arm, multicenter, phase ll clinical trial to evaluate the efficacy and safety of Zuberitamab and Bendamustine combination treatment in treatment-naïve follicular lymphoma patients.

Conditions

• Follicular Lymphoma (FL)

Interventions

Type	Name	Description
DRUG	Zuberitamab	375 mg/m², administered on Day 1 (D1) of Cycles 1-6 (C1-C6)
DRUG	Bendamustine	90 mg/m², administered on D1-2 of C1-C6

Timeline

• Start date: 2025-02-01
• Primary completion: 2028-02-01
• Completion: 2034-02-01
• First posted: 2025-01-03
• Last updated: 2025-01-03

Locations

1 site across 1 country: China